Unique ID issued by UMIN | UMIN000022239 |
---|---|
Receipt number | R000025616 |
Scientific Title | Efficacy and safety of thrice-weekly insulin degludec in elderly patients with type 2 diabetes |
Date of disclosure of the study information | 2016/05/08 |
Last modified on | 2018/07/18 12:44:13 |
Efficacy and safety of thrice-weekly insulin degludec in elderly patients with type 2 diabetes
Thrice-weekly insulin degludec regimen
Efficacy and safety of thrice-weekly insulin degludec in elderly patients with type 2 diabetes
Thrice-weekly insulin degludec regimen
Japan |
Type 2 diabetes
Endocrinology and Metabolism |
Others
NO
The aim of this study was to investigate the efficacy and safety of thrice-weekly insulin degludec (IDeg) therapy in elderly patients with type 2 diabetes who need insulin therapy but cannot perform self-injection.
Safety,Efficacy
Glycemic controlassessed by continuous glucose monitoring over 7 days
The percent duration of hypo- (<70 mg/dL and hyper- (>200 mg/dL) glycemia
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Medicine |
After becoming stable on once-daily insulin degludec treatment, OD group was assigned to continue once-daily injection.
After becoming stable on once-daily insulin degludec treatment, TW group was switched to thrice-weekly injection.
IDeg was injected at twice the OD dose before lunch on Monday, Wednesday, and Friday.
20 | years-old | <= |
100 | years-old | > |
Male and Female
The inclusion criteria were the following relative indications for insulin treatment according to the Japan Diabetes Society: 1) detection of marked hyperglycemia (e.g., fasting plasma glucose > 250 mg/dL or casual plasma glucose > 350 mg/dL) in the non-insulin-dependent state, 2) failure to achieve good glycemic control with oral hypoglycemic agents, 3) deterioration of the nutritional status in a lean patient, or 4) to achieve active control of glucose toxicity when this is needed.
The exclusion criteria were the following absolute indications for insulin treatment: 1) an insulin-dependent state, 2) diabetic coma, 3) hyperglycemia complicated by severe liver or kidney disease, 4) serious infection, trauma, or major surgery, 5) intravenous alimentation. Patients who had no difficulty performing self-injection of insulin were also excluded.
20
1st name | |
Middle name | |
Last name | Yasushi Tanaka |
St. Marianna University School of Medicine
Division of Metabolism and Endocrinology, Department of Internal Medicine
2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan
0449778111
smu.tainai@gmail.com
1st name | |
Middle name | |
Last name | Yoshio Nagai |
St. Marianna University School of Medicine
Division of Metabolism and Endocrinology, Department of Internal Medicine
2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan
0449778111
ynagai@marianna-u.ac.jp
St. Marianna University School ofMedicine
Self funding
Self funding
NO
2016 | Year | 05 | Month | 08 | Day |
Published
https://www.jstage.jst.go.jp/article/endocrj/63/12/63_EJ16-0252/_article
Completed
2014 | Year | 11 | Month | 01 | Day |
2014 | Year | 11 | Month | 18 | Day |
2016 | Year | 05 | Month | 08 | Day |
2018 | Year | 07 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025616
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |